• <input id="ycg2u"></input>
    <legend id="ycg2u"></legend>
    <strong id="ycg2u"><u id="ycg2u"></u></strong>
  • Enable Accessibility Enable Accessibility


    Changing the future of healthcare through regenerative medicine and drug discovery

    CiRA×Takeda =   

    Combined strengths, high expectations

    T-CiRA is a joint research program by the Center for iPS Cell Research and Application (CiRA), Kyoto University and Takeda Pharmaceutical Company Limited. Over a 10-year period and under the direction of CiRA, this joint program will conduct research to develop clinical applications of iPS cells.


    Living with NGLY1 deficiency: Grace’s Story

    Takeda supports the research of innovative therapies for rare diseases. NGLY1 deficiency is currently being studied under the Takeda-Center for iPS Cell Research and Applications (T-CiRA) program in partnership with RIKEN.

    Watch Grace’s story to see how the hard work of many has the potential to impact the lives of those living with this ultra-rare disease.

    This video is for disease awareness purposes only.


    About T-CiRA.png

    Leaders message.png

    What We Do.png


    Project Members.png

    Inside T-CiRA.png

    Research Achievements_pc.png

    Future of iPSC.png

    For inquiries regarding T-CiRA

    Takeda Pharmaceutical Company Limited Shonan Health Innovation Park

    Phone: +81(0)466-32-2111
    Fax: +81(0)466-29-4405
    Email: T_CiRA@takeda.co.jp

    Join our journey to realize new therapies

    We are recruiting scientists for promoting iPS cell research and with skills for cell manufacturing management, who will be affiliated with Center for iPS Cell Research and Application (CiRA), Kyoto University.




    Related Pages


    Shonan Health Innovation Park

    The T-CiRA research laboratory has been established at the Shonan Health Innovation Park